Phase I Clinical Trial Completes Using Cell Line Expertise at Cobra Biologics

News   Apr 03, 2017 | Original story from Cobra Biologics

 
Phase I Clinical Trial Completes Using Cell Line Expertise at Cobra Biologics

Peter Coleman, CEO of Cobra Biologics

 
 
 

RELATED ARTICLES

Sex Differences Revealed: Heart Failure Death Rates

News

Death from heart failure in men and women compared in a study of over 90 000 patients

READ MORE

Fetal Gene Therapy Prevents Lethal Neurodegenerative Disease

News

Researchers have successfully prevented the development of a fatal neurodegenerative disorder, Gaucher disease, using fetal gene therapy, in mice. The study highlights the potential of using this approach to combat lethal neurodegenerative diseases affecting newborns.

READ MORE

Key Role for Enzyme in Chagas Disease Response

News

Researchers describe the central role played by an enzyme called phosphatidylinositol 3-kinase gamma (PI3Kγ) in regulating the immune response against Trypanosoma cruzi, the protozoan parasite that causes Chagas disease.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Analysis & Separations Drug Discovery Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE
 

We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy